Interview: Madhusudhan Venkatachari – CEO, Natco Pharma Canada
Madhu Venkat, CEO of Natco Pharma Canada, highlights the company’s portfolio strategy, its strategic road map to be the first mover and become a leading generic supplier in oncology by…
Natco Pharma (Canada) Inc. is a Canadian subsidiary of Natco Pharma Limited, India. Natco Pharma Limited is a vertically integrated pharmaceutical company heavily focused in R&D and in manufacturing drug intermediates, API and finished formulations. It has a global network and customer centric approach.
The company exports API’s and Formulations to around 50 countries across the globe. Well known for its impressive portfolio of Oncology, Neurology and CNS drugs, it is bringing to market niche pharmaceuticals.
Natco Pharma has been supplying high quality pharmaceuticals to the Canadian market for more than five years, and, since its formation, has set up a very professional Quality, Regulatory, Warehousing, Marketing, Distribution and Logistics capability to service the Canadian market.
The company is slated to launch some of its already approved generic products and in the process of getting approvals for some very niche and very significant pipeline of pharmaceuticals.
Contact:
Address: 2550 Argentina Road, Suite 116, Mississauga, ON, L5N 5R1 Canada
Tel.: +1 (905) 997 3353
Website: http://natcopharma.ca/
Madhu Venkat, CEO of Natco Pharma Canada, highlights the company’s portfolio strategy, its strategic road map to be the first mover and become a leading generic supplier in oncology by…
Andrew Casey, President and CEO of BIOTECanada, the national biotech association, provides an update on the Canadian biotech landscape, the strength of the Canadian R&D ecosystem, the growing investor community…
Patrick Nadeau, vice-president (business development, marketing and operations) of Lupin Pharma Canada, highlights the journey of Lupin Pharma within Canada since its 2014 establishment, the strategic importance of the Canadian…
Roseann O’Reilly Runte, president of the Canada Foundation for Innovation (CFI) speaks about the role and the importance of innovation in the Canadian life sciences industry and how Canada is…
Peter Brenders, general manager of Sanofi Genzyme Canada, highlights the strategic significance of the Canadian affiliate, which has seen double-digit growth every quarter for the past five and a half…
Dr. Fernand Labrie shares the significant achievements of Endoceutics, in launching its first breakthrough product for post-menopausal vulvar and vaginal atrophy, known as the ‘female Viagra’, the innovations behind the…
Dr. Jeremy B. Desai, CEO & President of Apotex, the Canadian international generics powerhouse, discusses his mandate in 2014 to take the company global, the challenges and opportunities of increasing…
Niven Al-Khoury, President of Sanofi Canada, highlights the strong presence that Sanofi has established in the country over the past 100 years, some of the notable historical achievements from collaboration…
Alok Kanti, president and CEO of Bayer Canada, draws upon his 27 years of international experience with Bayer to discuss the strategic significance of the Canadian affiliate to Bayer’s global…
Michael Tremblay, president and CEO of Astellas Pharma Canada, Inc., draws upon his four decades of experience within the Canadian pharmaceutical industry to discuss his thoughts on the need for…
Douglas Clark, Executive Director of the Patented Medicine Prices Review Board (PMPRB), Canada’s federal price regulator for patented medicines, highlights the PMPRB’s mandate to protect consumers against excessive prices for…
Jim Keon, President of the CGPA, discusses how the Canadian generics industry is adapting to the current period of political transition and how it engages in talks with the government…
Jonathan Ross Goodman, founder and CEO of Knight Therapeutics Inc., discusses the unique backstory behind the founding of the company, coming on the heels of the sale of Paladin Labs…
See our Cookie Privacy Policy Here
